GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1361 Medetomidine HClSummary: Selective α2-adrenoceptor agonist -
B2299 MozavaptanSummary: novel competitive vasopressin receptor antagonist -
B1366 Naftopidil DiHClSummary: Selective 5-HT1A and α1-adrenergic receptor antagonist -
B1986 NedaplatinSummary: DNA synthesis inhibitor -
B1995 (+,-)-Octopamine HClSummary: adrenoceptor agonist -
B1810 PenfluridolTarget: Voltage-gated Calcium Channels (CaV)Summary: Dopamine receptor antagonist -
B1814 Pheniramine MaleateSummary: Histamine receptor antagonist -
B1816 Pilocarpine HClSummary: Nonselective muscarinic acetylcholine receptor agonist -
B2253 PrucaloprideSummary: 5-HT4A and 5-HT4B receptor agonist -
B1822 Prucalopride SuccinatSummary: Selective, high affinity 5-HT4 receptor agonist

